1st Announcement: “HTA Seminar”
Tuesday, June 30, 2020
9:00 – 17:00
Basel, Switzerland
Novartis campus

Health Technology Assessment (HTA) is an instrumental part of the process in obtaining reimbursement and market access for pharmaceuticals and medical device products in countries around the world.

Statisticians have substantially contributed to meet the demands of these different agencies. However, it is apparent that much more can still be accomplished, especially when considering new data sources (molecular profiles and omics, sensors and wearables), advanced analytics, precision medicine, novel clinical decision support tools, and regulatory labels purely based on real world data.

This seminar will consist of presentations as well as moderated panel discussions with the experts to discuss 3 overarching HTA topics:

- What has been accomplished in the last 10 years
- What challenges will the scientific advances and new data sources create for different stakeholders:
  - How will these affect clinical R&D and commercialization in the biopharmaceutical and medical device industry?
  - How will regulators and HTA balance traditional clinical trials and new real world evidence?
  - What will the impact be for patients and on society?
- Where are the major gaps and what still needs to be done

The Basel Biometric Society (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) are pleased to host a scientific meeting on this relevant topic with experts from the pharmaceutical industry, academia and the European HTA bodies.

Currently confirmed presenters and/or panelists:

Jens Grüger
Boston Consulting Group Zurich, Univ. of Washington, ISPOR President-elect

Chrissie Fletcher
GSK HQs, UK and Chair, PSI HTA SIG celebrating its 10 year anniversary

Skip Olson
Novartis HQs, Switzerland

Friedhelm Leverkus
Pfizer Germany

John Doyle
Pfizer HQs and Columbia Univ., New York, USA

Anja Schiel
Norwegian Medicines Agency, Norway

Christoph Schürmann
IQWiG, Germany

Marc Buyse
IDDI, Belgium

Mark Nuijten
Erasmus Univ., Netherlands

Fred Sorenson
Xcenda, Switzerland

The program, which will include several additional speakers who will be presenting on relevant topics pertaining to HTA, is expected to be available in March.

Venue
Novartis Pharmaceuticals,
Novartis Campus
Fabrikstrasse 10
Basel, Switzerland

Registration
On or before 22 May 2020
Industry rate: €100.00
Academic rate: €50.00

After 22 May 2020
Industry rate: €150.00
Academic rate: €75.00

TO REGISTER PLEASE GO TO: www.efspi.org

There you can also register at a reduced rate for the joint BBS/EFSPI meeting on Estimands in Oncology, to be held the day before at the same venue.

Queries contact:
EFSPI Secretariat
Tel: +44 (0)1625 664549
efs@kingstonsmith.co.uk

For information regarding the scientific content, contact:
Fred Sorenson
Tel.: +41 78 949 32 44
Fred.sorenson@xcenda.com

Note that there is only limited parking space. Public transport is recommended.